Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Monday, December 23, 2024
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
RTX’s Collins Aerospace announces avionics modernization program for King Air and…
Aptar and Nadara Collaborate to Drive Renewable Energy Generation in Europe
KalVista Appoints Jeb Ledell as Chief Operating Officer
Biocytogen Announces Adcendo ApS Exercises Antibody Option
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
Evrysdi
Evrysdi
Healthcare
FDA Approves Genentech’s Evrysdi for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
Business Wire
-
May 31, 2022
Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam)...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
RTX’s Collins Aerospace announces avionics modernization program for King Air and Hawker aircraft
Aptar and Nadara Collaborate to Drive Renewable Energy Generation in Europe
KalVista Appoints Jeb Ledell as Chief Operating Officer
Load more
